TuHURA Biosciences (NASDAQ:HURA) to Present at the Virtual Investor "New to the Street" Event
TuHURA Biosciences (NASDAQ:HURA), a Phase 3 registration-stage immune-oncology company, will present at the Virtual Investor "New to the Street" Event on October 30, 2024, at 4:00 PM ET. Dr. Jim Bianco, President and CEO, will provide a corporate overview and business outlook during a live moderated webcast.
Investors can submit questions live during the event, with the company aiming to answer as many as possible. The presentation will be available on TuHURA's website, with a replay accessible for 90 days following the live event.
TuHURA focuses on developing novel technologies to overcome resistance to cancer immunotherapy. This event offers an opportunity for investors to gain insights into the company's progress and future plans in the immune-oncology field.
TuHURA Biosciences (NASDAQ:HURA), un'azienda in fase di registrazione di terzo livello nel settore dell'immuno-oncologia, parteciperà all'evento virtuale per investitori "New to the Street" il 30 ottobre 2024, alle 16:00 ET. Il Dott. Jim Bianco, Presidente e CEO, fornirà una durante una diretta in webcast moderata.
Gli investitori possono inviare domande in diretta durante l'evento, con l'obiettivo dell'azienda di rispondere a quante più domande possibile. La presentazione sarà disponibile sul sito web di TuHURA, con una registrazione accessibile per 90 giorni dopo l'evento dal vivo.
TuHURA si concentra sullo sviluppo di tecnologie innovative per superare la resistenza all'immunoterapia contro il cancro. Questo evento offre un'opportunità agli investitori per ottenere informazioni sui progressi dell'azienda e sui suoi piani futuri nel campo dell'immuno-oncologia.
TuHURA Biosciences (NASDAQ:HURA), una empresa en fase de registro de tercera fase en el campo de la inmuno-oncología, se presentará en el evento virtual para inversores "New to the Street" el 30 de octubre de 2024, a las 4:00 PM ET. El Dr. Jim Bianco, Presidente y CEO, ofrecerá una visión general de la empresa y una perspectiva comercial durante una transmisión web en vivo moderada.
Los inversores pueden enviar preguntas en vivo durante el evento, con el objetivo de que la empresa responda tantas como sea posible. La presentación estará disponible en el sitio web de TuHURA, con una repetición accesible durante 90 días después del evento en vivo.
TuHURA se centra en el desarrollo de nuevas tecnologías para superar la resistencia a la inmunoterapia contra el cáncer. Este evento ofrece una oportunidad a los inversores para obtener información sobre el progreso de la empresa y sus planes futuros en el campo de la inmuno-oncología.
TuHURA Biosciences (NASDAQ:HURA), 면역종양학 분야의 3상 등록 단계 회사는 2024년 10월 30일 오후 4시 ET에 열리는 가상 투자자 이벤트 "New to the Street"에 참여할 예정입니다. 짐 비안코 박사, 사장 및 CEO가 실시간 진행된 웹캐스트에서 회사 개요 및 사업 전망을 제공합니다.
투자자들은 이벤트 도중 실시간으로 질문을 제출할 수 있으며, 회사는 가능한 많은 질문에 답변할 계획입니다. 프레젠테이션은 TuHURA의 웹사이트에서 제공되며, 이벤트 후 90일 동안 재생 가능합니다.
TuHURA는 암 면역 요법에 대한 저항을 극복하기 위한 새로운 기술 개발에 중점을 두고 있습니다. 이 이벤트는 투자자에게 회사의 진전 및 면역종양학 분야의 미래 계획에 대한 통찰력을 얻을 수 있는 기회를 제공합니다.
TuHURA Biosciences (NASDAQ:HURA), une entreprise en phase d'enregistrement de phase 3 dans le domaine de l'immuno-oncologie, présentera lors de l'événement virtuel pour investisseurs "New to the Street" le 30 octobre 2024 à 16h00 ET. Dr. Jim Bianco, Président et CEO, fournira un aperçu de l'entreprise et des perspectives commerciales lors d'un webinaire modéré en direct.
Les investisseurs peuvent soumettre des questions en direct pendant l'événement, l'entreprise visant à répondre à autant de questions que possible. La présentation sera disponible sur le site Web de TuHURA, avec un accès à la rediffusion pendant 90 jours après l'événement en direct.
TuHURA se concentre sur le développement de nouvelles technologies pour surmonter la résistance à l'immunothérapie contre le cancer. Cet événement offre aux investisseurs une opportunité d'obtenir des informations sur les progrès de l'entreprise et ses plans futurs dans le domaine de l'immuno-oncologie.
TuHURA Biosciences (NASDAQ:HURA), ein Unternehmen im Registrierungsstadium der Phase 3 im Bereich der Immunonkologie, wird am 30. Oktober 2024 um 16:00 Uhr ET beim virtuellen Investorenevent "New to the Street" präsentieren. Dr. Jim Bianco, Präsident und CEO, wird in einem live moderierten Webcast eine Unternehmensübersicht und Geschäftsausblick geben.
Investoren können während der Veranstaltung live Fragen einreichen, wobei das Unternehmen anstrebt, so viele wie möglich zu beantworten. Die Präsentation wird auf der Website von TuHURA verfügbar sein, mit einer Wiederholung, die 90 Tage lang verfügbar ist nach der Live-Veranstaltung.
TuHURA konzentriert sich auf die Entwicklung neuartiger Technologien zur Überwindung von Resistenzen gegen Krebsimmuntherapien. Diese Veranstaltung bietet Investoren eine Gelegenheit, Einblicke in die Fortschritte des Unternehmens und die zukünftigen Pläne im Bereich der Immunonkologie zu gewinnen.
- None.
- None.
Live moderated webcast with Dr. Jim Bianco, President and Chief Executive Officer of TuHURA on Wednesday, October 30th at 4 PM ET
TAMPA, FL / ACCESSWIRE / October 22, 2024 / TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 registration-stage immune-oncology company developing novel technologies to overcome resistance to cancer immunotherapy, today announced that it will present at the Virtual Investor New to the Street Event on Wednesday, October 30, 2024 at 4:00 PM ET.
As part of the event, Dr. Jim Bianco, President and Chief Executive Officer of TuHURA will provide a corporate overview and business outlook. In addition to the moderated discussion, investors and interested parties will have the opportunity to submit questions live during the event. The Company will answer as many questions as possible in the time allowed.
A live video webcast of the presentation will be available on the Events page of the Investors section of the Company's website (www.tuhurabio.com). A webcast replay will be available two hours following the live presentation and will be accessible for 90 days.
About TuHURA Biosciences, Inc.
TuHURA Biosciences, Inc. is a Phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. TuHURA's lead innate immune response agonist candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. TuHURA is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda® (pembrolizumab) in first line treatment for advanced or metastatic Merkel Cell Carcinoma.
In addition to its innate immune response agonist candidates, TuHURA is leveraging its Delta receptor technology to develop first-in-class bi-specific ADCs, and PDCs targeting Myeloid Derived Suppressor Cells to inhibit their immune suppressing effects on the tumor microenvironment to prevent T cell exhaustion and acquired resistance to checkpoint inhibitors and cellular therapies.
For more information, please visit tuhurabio.com and connect with TuHURA on Facebook, X, and LinkedIn.
Investor Contact:
Jenene Thomas
JTC Team, LLC
908.824.0775
tuhura@jtcir.com
SOURCE: TuHURA Biosciences, Inc.
View the original press release on accesswire.com
FAQ
When is TuHURA Biosciences (HURA) presenting at the Virtual Investor 'New to the Street' Event?
Who will be presenting for TuHURA Biosciences (HURA) at the upcoming investor event?
What will be discussed during TuHURA Biosciences' (HURA) presentation?
Can investors ask questions during TuHURA Biosciences' (HURA) presentation?
Where can I watch TuHURA Biosciences' (HURA) presentation?
